Reported incidences of agranulocytosis, hyperkalemia, and anaphylaxis. The use of nafamostat has been reported to cause cardiac arrest in patients receiving dialysis due to a sudden change in the patient's condition such as dyspnea. A study suggests that the drug and its metabolites may inhibit the amiloride-sensitive sodium (Na) conductance at the collecting ducts, resulting in an inhibition of K secretion and hyperkalemia A19240. Reported LD50 value from intravenous administration in rats is 16.4mg/kg.
Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Nafamostat. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Nafamostat. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Nafamostat. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Nafamostat is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Nafamostat. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Nafamostat. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Nafamostat is combined with Obinutuzumab. |
| Rivaroxaban | Nafamostat may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Nafamostat is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Nafamostat. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Nafamostat. |
| Urokinase | Urokinase may increase the anticoagulant activities of Nafamostat. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Nafamostat. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Nafamostat. |
| Bupropion | The excretion of Nafamostat can be decreased when combined with Bupropion. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Nafamostat. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Nafamostat. |
| Quinine | The therapeutic efficacy of Nafamostat can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Nafamostat can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Nafamostat. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Nafamostat. |
| Pentoxifylline | The therapeutic efficacy of Nafamostat can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Nafamostat. |
| Levocarnitine | The therapeutic efficacy of Nafamostat can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Nafamostat. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Nafamostat. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Nafamostat. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Nafamostat. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Nafamostat. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Nafamostat. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Nafamostat. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Nafamostat. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nafamostat. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Nafamostat. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Nafamostat. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Nafamostat. |
| Equol | Equol may decrease the anticoagulant activities of Nafamostat. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Nafamostat. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Nafamostat. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Nafamostat. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Nafamostat. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Nafamostat. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Nafamostat. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Nafamostat. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Nafamostat. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Nafamostat. |
| Estriol | Estriol may decrease the anticoagulant activities of Nafamostat. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Nafamostat. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Nafamostat. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Nafamostat. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Nafamostat. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Nafamostat. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Nafamostat. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Nafamostat. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Nafamostat. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Nafamostat. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Nafamostat. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Nafamostat. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Nafamostat. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Nafamostat. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Nafamostat. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Nafamostat. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Nafamostat. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Nafamostat. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Nafamostat. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Nafamostat. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Nafamostat. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Nafamostat. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Nafamostat. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Nafamostat. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Nafamostat. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Nafamostat. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Nafamostat. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Nafamostat. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Nafamostat. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Nafamostat. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Nafamostat. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Nafamostat. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Nafamostat. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Nafamostat. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Nafamostat. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Nafamostat. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Nafamostat. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Nafamostat. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Nafamostat. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Nafamostat. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Nafamostat. |